Effect of fibroblast co‑culture on the proliferation, viability and drug response of colon cancer cells

Koh,Byumseok; Jeon,Hyojin; Kim,Dahee; Kang,Dukjin; Kim,Kwang  Rok

doi:10.3892/ol.2018.9836

Effect of fibroblast co‑culture on the proliferation, viability and drug response of colon cancer cells

Authors:
- Byumseok Koh
- Hyojin Jeon
- Dahee Kim
- Dukjin Kang
- Kwang Rok Kim
View Affiliations

Affiliations: Bio Platform Technology Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea, Innovative Target Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea, Center for Bioanalysis, Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
Published online on: December 14, 2018 https://doi.org/10.3892/ol.2018.9836
Pages: 2409-2417
Copyright: © Koh et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interactions between cancer cells and the surrounding fibroblasts serve an important role in cancer proliferation. Colon cancer co‑culture model with colon fibroblasts and two metastatic models with lung and skin fibroblasts were established, and the co‑culture effects on colon cancer cell proliferation, apoptosis and drug response were evaluated. Co‑culture with CCD‑18Co and BJ reduces SW480 cell proliferation by 4.2 and 5.3%, respectively, while WI‑38 acts as a positive regulator and increases SW480 cell proliferation by 36%. CCD‑18Co and BJ co‑culture can also enhance XAV939 potency against SW480 cells by 16.8 and 27.3%; however, WI‑38 co‑culture reduces the effect of XAV939 by 38.2%. The present results suggest that, depending on fibroblast type, co‑culture can have a positive/negative influence on colon cancer growth; therefore, care should be taken when considering fibroblasts as a target for future cancer therapies.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH and Lee KH: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 47:127–141. 2015. View Article : Google Scholar : PubMed/NCBI
3	Wang D, Rai B, Qi F, Liu T, Wang J, Wang X and Ma B: Influence of the Twist gene on the invasion and metastasis of colon cancer. Oncol Rep. 39:31–44. 2018.PubMed/NCBI
4	Duan L, Deng L, Wang D, Ma S, Li C and Zhao D: Treatment mechanism of matrine in combination with irinotecan for colon cancer. Oncol Lett. 14:2300–2304. 2017. View Article : Google Scholar : PubMed/NCBI
5	Li K, Guo J, Wu Y, Jin D, Jiang H, Liu C and Qin C: Suppression of YAP by DDP disrupts colon tumor progression. Oncol Rep. 39:2114–2126. 2018.PubMed/NCBI
6	De Roock W, De Vriendt V, Normanno N, Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
7	Moriarity A, O'Sullivan J, Kennedy J, Mehigan B and McCormick P: Current targeted therapies in the treatment of advanced colorectal cancer: A review. Ther Adv Med Oncol. 8:276–293. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hagan S, Orr MC and Doyle B: Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J. 4:32013. View Article : Google Scholar : PubMed/NCBI
9	Heinemann V, Douillard JY, Ducreux M and Peeters M: Targeted therapy in metastatic colorectal cancer-an example of personalized medicine in action. Cancer Treat Rev. 39:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
10	Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM and Kesselheim AS: Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 176:1826–1833. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hay M, Thomas DW, Craighead JL, Economides C and Rosenthal J: Clinical development success rates for investigational drugs. Nat Biotechnol. 32:40–51. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sun Y: Tumor microenvironment and cancer therapy resistance. Cancer Lett. 380:205–215. 2016. View Article : Google Scholar : PubMed/NCBI
13	Fang H and Declerck YA: Targeting the tumor microenvironment: From understanding pathways to effective clinical trials. Cancer Res. 73:4965–4977. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G and Sun Y: New horizons in tumor microenvironment biology: Challenges and opportunities. BMC Med. 13:452015. View Article : Google Scholar : PubMed/NCBI
15	Peddareddigari VG, Wang D and Dubois RN: The Tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron. 3:149–166. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhou W, Xu G, Wang Y, Xu Z, Liu X, Xu X, Ren G and Tian K: Oxidative stress induced autophagy in cancer associated fibroblast enhances proliferation and metabolism of colorectal cancer cells. Cell Cycle. 16:73–81. 2017. View Article : Google Scholar : PubMed/NCBI
17	O'Toole A, Michielsen AJ, Nolan B, Tosetto M, Sheahan K, Mulcahy HE, Winter DC, Hyland JM, O'Connell PR, Fennelly D, et al: Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. Br J Cancer. 111:927–932. 2014. View Article : Google Scholar : PubMed/NCBI
18	Jacobs J, Smits E, Lardon F, Pauwels P and Deschoolmeester V: Immune checkpoint modulation in colorectal cancer: What's new and what to expect. J Immunol Res. 2015:1580382015. View Article : Google Scholar : PubMed/NCBI
19	Colangelo T, Polcaro G, Muccillo L, D'Agostino G, Rosato V, Ziccardi P, Lupo A, Mazzoccoli G, Sabatino L and Colantuoni V: Friend or foe?: The tumour microenvironment dilemma in colorectal cancer. Biochim Biophys Acta Rev Cancer. 1867:1–18. 2017. View Article : Google Scholar : PubMed/NCBI
20	Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, Laghi L, Barberis MC, Sessa F, Noonan DM and Albini A: The tumor microenvironment of colorectal cancer: Stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 8:1122010. View Article : Google Scholar : PubMed/NCBI
21	Marsh T, Pietras K and McAllister SS: Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta. 1832:1070–1078. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI
23	Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
24	Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A, et al: Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 210:2851–2872. 2013. View Article : Google Scholar : PubMed/NCBI
25	Ostman A and Augsten M: Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev. 19:67–73. 2009. View Article : Google Scholar : PubMed/NCBI
26	Iacopino F, Angelucci C and Sica G: Interactions between normal human fibroblasts and human prostate cancer cells in a co-culture system. Anticancer Res. 32:1579–1588. 2012.PubMed/NCBI
27	Tao L, Huang G, Song H, Chen Y and Chen L: Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett. 14:2611–2620. 2017. View Article : Google Scholar : PubMed/NCBI
28	Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H and Takeyama H: Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. Cancers (Basel). 7:2443–2458. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zabransky DJ, Yankasakas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, et al: HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci USA. 112:E6205–E6214. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB and Logsdon CD: Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68:918–926. 2008. View Article : Google Scholar : PubMed/NCBI
31	Liao D, Luo Y, Markowitz D, Xiang R and Reisfeld RA: Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 4:e79652009. View Article : Google Scholar : PubMed/NCBI
32	Cheng HH, Chu LY, Chiang LY, Chen HL, Kuo CC and Wu KK: Inhibition of cancer cell epithelial mesenchymal transition by normal fibroblasts via production of 5-methoxytryptophan. Oncotarget. 7:31243–31256. 2016.PubMed/NCBI
33	de Toledo M, Anguille C, Roger L, Roux P and Gadea G: Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One. 7:e483442012. View Article : Google Scholar : PubMed/NCBI
34	Majety M, Pradel LP, Gies M and Ries CH: Fibroblast influence survival and therapeutic response in a 3d Co-culture model. PLoS One. 10:e01279482015. View Article : Google Scholar : PubMed/NCBI
35	Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S and Yano S: Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res. 16:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
36	Villeneueve PJ and Sundaresan RS: Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg. 22:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
37	Nesseris I, Tsamakis C, Gregoriou S, Ditsos I, Christofidou E and Rigopoulos D: Cutaneous metastasis of colon adenocarcinoma: Case report and review of the literature. An Bras Dermatol. 88:(6 Suppl 1). S56–S58. 2013. View Article : Google Scholar
38	Liu Y, Zhang F, Zhang XF, Qi LS, Yang L, Guo H and Zhang N: Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. J Biomed Sci. 19:532012. View Article : Google Scholar : PubMed/NCBI
39	Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, et al: Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 74:3238–3247. 2014. View Article : Google Scholar : PubMed/NCBI
40	Labi V and Erlacher M: How cell death shapes cancer. Cell Death Dis. 6:e16752015. View Article : Google Scholar : PubMed/NCBI
41	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
42	Trédan O, Galmarini CM, Patel K and Tannock IF: Drug Resistance and the solid tumor microenvironment. J Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI
43	Segditsas S and Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 25:7531–7537. 2006. View Article : Google Scholar : PubMed/NCBI
44	Kim YE, Jeon HJ, Kim D, Lee SY, Kim KY, Hong J, Maeng PJ, Kim KR and Kang D: Quantitative proteomic analysis of 2D and 3D cultured colorectal cancer cells: Profiling of tankyrase inhibitor xav939-induced proteome. Sci Rep. 8:132552018. View Article : Google Scholar : PubMed/NCBI
45	Pagliara V, Saide A, Mitidieri E, d'Emmanuele di Villa Bianca R, Sorrentino R, Russo G and Russo A: 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lacking p53. Oncotarget. 7:50333–50348. 2016. View Article : Google Scholar : PubMed/NCBI
46	Fuchs C, Mitchell EP and Hoff PM: Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 32:491–503. 2006. View Article : Google Scholar : PubMed/NCBI
47	Weinländer G, Kornek G, Raderer M, Hejna M, Tetzner C and Scheithauer W: Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: High-dose oral tamoxifen and dexverapamil. J Cancer Res Clin Oncol. 123:452–455. 1997. View Article : Google Scholar : PubMed/NCBI